ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J01DH02 | G | Meropenem (trihydrate) - 1g | 7021 | 97003/12 | MIRAN | 1g | 1 | Injectable powder for solution | Infusion/IV | Pharmanet Drugstore S.A.R.L. | ACS Dobfar S.P.A. | Italy | 1,028,040 L.L | 23.08 | A2 | Julphar | United Arab Emirates | 12/12/20 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J01DH02 | B | Meropenem (trihydrate) - 1g | 10187 | 105319/1 | MERONEM | 1g | 10 | Injectable powder for solution | Infusion/IV | Droguerie Fattal S.A.L. | ACS Dobfar S.P.A. | Italy | 26,272,722 L.L | 19.35 | D | Pfizer Ltd | UK | 12/12/20 | 0 |
J01DH02 | G | Meropenem (trihydrate) - 1g | 6542 | 166843/11 | MEROPENEM LABATEC | 1g | 10 | Injectable powder for solution | Infusion/IV | Levant Alie Houses S.A.L. | ACS Dobfar S.P.A. | Italy | 12,764,391 L.L | 21.26 | C | Labatec Pharma SA | Switzerland | 12/12/20 | 0 |
J01DH02 | G | Meropenem (trihydrate) - 1g | 6997 | 186261/13 | MEROPENEM PANPHARMA | 1g | 10 | Injectable powder for solution | Infusion/IV | Minapharm Halabi | ACS Dobfar S.P.A. | Italy | 16,843,941 L.L | 19.35 | D | Panpharma | France | 12/12/20 | 0 |
J01DH02 | G | Meropenem (trihydrate) - 1g | 7198 | 97227/12 | MEROPENEM/ ANFARM | 1g | 10 | Injectable powder for solution | Infusion/IV | Medi drug International SAL (MDI) | Anfarm Hellas SA | Greece | 7,624,551 L.L | 21.26 | C | Anfarm Hellas SA | Greece | 12/12/20 | 0 |
J01DH02 | G | Meropenem - 1g | 8142 | 186823/14 | ARCHIFAR | 1g | 10 | Injectable powder for solution | Infusion/IV | New Allpharma | Medochemie Ltd | Cyprus | 14,168,342 L.L | 19.35 | D | Medochemie Ltd | Cyprus | 12/12/20 | 0 |
J01DH02 | G | Meropenem - 1g | 11372 | 112620/1 | MEROZAN | 1g | 10 | Injectable powder for solution | Infusion/IV | Macromed S.A.R.L. | Demo SA | Greece | 7,634,958 L.L | 21.26 | C | Demo SA | Greece | 12/12/20 | 0 |
J01DH02 | G | Meropenem (trihydrate) - 1000mg | 6513 | 222474/08 | ROPENEM 1000 BENTA | 1g | 1 | Injectable powder for solution | Infusion/IV | Benta Trading Co s.a.l. | Benta SAL | Lebanon | 1,254,253 L.L | 23.08 | B | 12/12/20 | 0 | ||
J01DH02 | G | Meropenem (trihydrate) - 1g | 6894 | 96607/12 | AROPEM | 1g | 1 | Injectable powder for solution | Infusion/IV | Raymond Georges Abou Adal & Co | Zambon Switzerland Ltd Switzerland for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 1,695,033 L.L | 23.08 | B | 12/12/20 | 0 | ||
J01DH02 | G | Meropenem (trihydrate) - 1g | 10097 | 29319/1 | MEROLIN | 1g | 3 | Injectable powder for solution | Infusion/IV | Drugstore 3U S.A.R.L. | Packed by Pharmadex SAL Lebanon under license from ACS Dobfar SpA, Italy | Lebanon | 5,006,110 L.L | 23.08 | B | 12/12/20 | 0 | ||
J01DH02 | G | Meropenem - 1g | 10903 | 158519/1 | AROPEM | 1g | 1 | Injectable powder for solution | Infusion/IV | Raymond Georges Abou Adal & Co | Savior Lifetec Corporation, Taiwan for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 1,695,033 L.L | 23.08 | B | 12/12/20 | 0 | ||
J01DH02 | G | Meropenem - 1g | 10927 | 50822/1 | AROPEM | 1g | 1 | Injectable sterile lyophilised powder for solution | Infusion/IV | Raymond Georges Abou Adal & Co | ACS Dobfar SpA, Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 1,695,033 L.L | 23.08 | B | 12/12/20 | 0 | ||
J01DH02 | G | Meropenem - 1g | 11563 | 158323/1 | AROPEM | 1g | 24 | Injectable sterile lyophilised powder for solution | Infusion/IV | Raymond Georges Abou Adal & Co | ACS Dobfar SpA, Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 29,098,108 L.L | 10.71 | E1 | 12/12/20 | 0 |